Cytopoint

RSS

lokivetmab

Authorised
This medicine is authorised for use in the European Union.

Overview

Cytopoint is a veterinary medicine used to treat atopic and allergic dermatitis in dogs. Dermatitis is inflammation of the skin that is linked to allergy, often to things in the environment such as house dust mites and pollens. Once the dog’s skin becomes damaged by scratching and rubbing, secondary bacterial and yeast infections may develop as well. 

Cytopoint contains the active substance lokivetmab.

This EPAR was last updated on 15/09/2021

Authorisation details

Product details
Name
Cytopoint
Agency product number
EMEA/V/C/003939
Active substance
lokivetmab
International non-proprietary name (INN) or common name
lokivetmab
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QD11AH91
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
25/04/2017
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

09/09/2020 Cytopoint - EMEA/V/C/003939 - II/0009

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Other dermatological preparations

  • Agents for dermatitis, excluding corticosteroids

Therapeutic indication

Treatment of clinical manifestations of atopic dermatitis in dogs.

Assessment history

Related content

How useful was this page?

Add your rating
Average
3 ratings
1 rating
2 ratings
5 ratings